Table 4.

Treatment‐Emergent Adverse Events

	Renal Classification According to CrCl
	Normal (n = 6)	Mild (n = 6)	Moderate (n = 6)	Severe (n = 6)	ESRDa (n = 6)	Total (n = 6)
Subjects with any TEAE, n (%)	2 (33.3)	0 (0.0)	0 (0.0)	0 (0.0)	4 (66.7)	6 (20)
Decreased appetite	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.3)
Hyperkalemia	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)	1 (3.3)
Dizziness	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (50.5)	3 (10.0)
Somnolence	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (33.3)	2 (6.7)
Headache	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.3)
Vomiting	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	2 (33.3)	2 (6.7)
Constipation	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.3)

CrCl, creatinine clearance; ESRD, end‐stage renal disease; TEAE, treatment‐emergent adverse event.

^a4‐hour hemodialysis 24 hours after drug administration.